Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.38 |
| ▸ | BRAF | P15056 | 4/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.36 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.36 |
| ▸ | CIT | O14578 | 2/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.36 |
| ▸ | STK10 | O94804 | 2/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | RAF1 | P04049 | 2/20 | 0.36 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9384038 | 0.84 | KMT2A (0.55) | KMT2AMAPTFYNMAPK1 | |
| SCHEMBL27332971 | 0.82 | MAPT (0.42) | DYRK1AKMT2AMAPTPIK3CDPIK3CB | |
| SCHEMBL5017265 | 0.82 | DYRK1A (0.41) | DYRK1AKMT2AMAPTFYNPIK3CD | |
| SCHEMBL5017267 | 0.82 | DYRK1A (0.41) | DYRK1AKMT2AMAPTFYNPIK3CD | |
| SCHEMBL5015487 | 0.82 | DYRK1A (0.41) | DYRK1AKMT2AMAPTFYNPIK3CD | |
| SCHEMBL20442664 | 0.81 | SMN1; SMN2 (0.42) | KMT2AMAPT | |
| SCHEMBL5346265 | 0.81 | KMT2A (0.56) | KMT2AMAPTFYNMAPK14CSNK1D | |
| SCHEMBL5016843 | 0.80 | AR (0.45) | KMT2AMAPTFYN | |
| SCHEMBL27325656 | 0.79 | MAPT (0.40) | DYRK1AKMT2AMAPTPIK3CDPIK3CB | |
| SCHEMBL5631192 | 0.78 | DYRK1A (0.38) | DYRK1AKMT2AMAPTPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176809-A1 | RAF INHIBITOR COMPOUNDS AND METHODS | LAIRD ELLEN | 2009-07-09 | — | — | US | disclosed |
| WO-2009077886-A1 | MULTI-LAYERED DEVICES FOR ANALYTE DETECTION | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
| US-7491829-B2 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. (US) | 2009-02-17 | — | — | US | disclosed |
| CN-101282960-A | RAF inhibitor compounds and methods | GENENTECH INC (US) | 2008-10-08 | — | — | CN | disclosed |
| EP-1313751-B1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| EP-1846391-A2 | RAF INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20060189627-A1 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. | 2006-08-24 | — | — | US | disclosed |
| WO-2006084015-A2 | RAF INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-6740642-B2 | ACTIVE AGAINST GRAM POSITIVE PATHOGENS SUCH AS STAPHYLOCOCCUS AUREUS, STREPTOCOCCUS PNEUMONIAE, GRAM NEGATIVE STRAINS SUCH AS HAEMOPHILUS INFLUENZAE; IMPROVED STABILITY | BASILEA PARMACEUTICA AG (CH) | 2004-05-25 | — | — | US | disclosed |
| US-20030199459-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG, A SWISS COMPANY (CH) | 2003-10-23 | — | — | US | disclosed |
| EP-1313751-A1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016380-A1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189627-A1 | RAF inhibitor compounds and methods | BRAF, RAF1, ARAF | DYRK1A 2654/4885KMT2A 3401/4885MAPT 4407/4885 |
| US-20090176809-A1 | RAF INHIBITOR COMPOUNDS AND METHODS | BRAF, RAF1, ARAF | DYRK1A 2654/4885KMT2A 3401/4885MAPT 4407/4885 |
| US-20030199459-A1 | Macrolides with antibacterial activity | MRPL21, MRPS22, MRPL12 | DYRK1A 4499/4885KMT2A 2571/4885MAPT 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.